Cns Pharmaceuticals IncCNSP
Price$5.24

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$15.9MTTM through 31 Dec 2025
Free Cash Flow -$15.2MTTM through 31 Dec 2025

Margins

Current

Returns

-350.5%ROE
-183.8%ROA

Balance Sheet Health

Debt / Equity0.05x
Net Debt-$7Mnet cash position
Cash & Equivalents$7.2M

Quality Metrics

Earnings-Beat Rate50.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Pharmaceutical Development$0
View details

Pivoting to an acquisition-driven growth model focused on differentiated clinical-stage neurology and oncology assets.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.